Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Retained Earnings (2019 - 2025)

IDEAYA Biosciences (IDYA) has disclosed Retained Earnings for 7 consecutive years, with -$736.5 million as the latest value for Q4 2025.

  • Quarterly Retained Earnings fell 18.25% to -$736.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$736.5 million through Dec 2025, down 18.25% year-over-year, with the annual reading at -$736.5 million for FY2025, 18.25% down from the prior year.
  • Retained Earnings hit -$736.5 million in Q4 2025 for IDEAYA Biosciences, down from $2.1 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $3.8 million in Q3 2024 to a low of -$736.5 million in Q4 2025.
  • Historically, Retained Earnings has averaged -$172.6 million across 5 years, with a median of -$141.5 million in 2021.
  • Biggest five-year swings in Retained Earnings: plummeted 453060.0% in 2021 and later skyrocketed 207.42% in 2025.
  • Year by year, Retained Earnings stood at -$712000.0 in 2021, then plummeted by 303.23% to -$2.9 million in 2022, then skyrocketed by 119.58% to $562000.0 in 2023, then crashed by 110925.8% to -$622.8 million in 2024, then dropped by 18.25% to -$736.5 million in 2025.
  • Business Quant data shows Retained Earnings for IDYA at -$736.5 million in Q4 2025, $2.1 million in Q3 2025, and $1.5 million in Q2 2025.